Therapeutic Asset Ratings

141 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
N,N-Dimethyltryptamine Stroke	Algernon Pharmaceuticals	P1	C (37)
TEONANACATL Stroke	Johns Hopkins University	P1	C (37)
Alirocumab Stroke	The First Affiliated Hospital with Nanjing Medical University	Early P1	C (34)
92.3% TO NMT 93.8% ETHANOL BY WEIGHT IN WATER Stroke	University Hospital, Bordeaux	N/A	D (28)
Alpha Tocopherol Stroke	University of Ioannina	N/A	D (28)
Alum Stroke	Peking Union Medical College Hospital		D (28)
Axitinib Stroke	Karolinska Institutet	N/A	D (28)
Bms-907351 Stroke	Karolinska Institutet	N/A	D (28)
Bont A Stroke	Kayseri City Hospital	N/A	D (28)
Bont Injections Stroke	Vastra Gotaland Region	N/A	D (28)
CAFFEINE Stroke	Peking Union Medical College Hospital		D (28)
CISATRACURIUM ION Stroke	University Hospital Heidelberg	N/A	D (28)
CITRIC ACID (CONSTITUENT OF CRANBERRY LIQUID PREPARATION) Stroke	Peking Union Medical College Hospital		D (28)
Desflurane Stroke	University Hospital Heidelberg	N/A	D (28)
DEXTROSE Stroke	Istanbul Physical Medicine Rehabilitation Training and Research Hospital	N/A	D (28)
Docetaxel Stroke	Chang Gung University	N/A	D (28)
Exenatide Stroke	Rigshospitalet, Denmark	N/A	D (28)
FLAVONE, 3,3',4',5,7-PENTAHYDROXY- Stroke	Peking Union Medical College Hospital		D (28)
FLUDEOXYGLUCOSE Stroke	University of California, Los Angeles		D (28)
Gefetinib Stroke	Chang Gung University	N/A	D (28)
Ipilimumab Stroke	Karolinska Institutet	N/A	D (28)
L-AMINO ACIDS Stroke	University of Ioannina	N/A	D (28)
LENVATINIB Stroke	Karolinska Institutet	N/A	D (28)
Letrozole Stroke	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta	N/A	D (28)
METARAMINOL Stroke	Singapore General Hospital	N/A	D (28)

Showing 101 to 125 of 141 assets

PreviousPage 5 of 6Next